Suggested remit: To appraise the clinical and cost effectiveness of inebilizumab within its marketing authorisation for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6430
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 03 November 2025 - 01 December 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6430 |
| 10 June 2025 | In progress. Please note that following on from information received from the company, this appraisal has been scheduled back into the work programme and the appraisal is now anticipated to begin during early January 2026 when we will write to you about how you can get involved. |
| 12 December 2024 | Referral |
| 02 August 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 10 April 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual